drugset / Trial / NCT04584255
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Phase 2
Active not recruiting
62 enrolled
Dana-Farber Cancer Institute
GlaxoSmithKline · collabJohns Hopkins University · collabTranslational Breast Cancer Research Consortium · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PALB2 mutations. The names of the study drugs involved in this study are: * Niraparib (Zejula) * Dostarlimab
Timeline
- Start
- 2020-12-18
- Primary completion
- 2025-07-01
- Completion
- 2029-07-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dostarlimab | Monoclonal antibody | — | Intravenous |
| Subject | Niraparib | Small molecule | — | Oral |